Investor presentation Full year 2019 69 n forces in next-generation adult patients with haemophilia A Targeting megaTAL mRNA + Lipid nanoparticle bluebird bio/Novo Nordisk’s joint approach Gene Protein Hepatocyte • megaTAL: Proprietary, patented technology, broad IP • Correcting FVIII-clotting factor deficiency • Potential life long effect • Possibility to explore additional therapeutic targets messenger ribonucleic acid; TAL: transcription activator-like.
Download PDF file